Altium Capital Management LLC Makes New $526,000 Investment in Fulcrum Therapeutics, Inc. (NASDAQ:FULC)

Altium Capital Management LLC acquired a new position in shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 111,812 shares of the company's stock, valued at approximately $526,000. Altium Capital Management LLC owned 0.21% of Fulcrum Therapeutics as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of FULC. Mariner LLC bought a new position in Fulcrum Therapeutics in the fourth quarter valued at approximately $78,000. Zacks Investment Management acquired a new position in shares of Fulcrum Therapeutics during the 4th quarter worth $99,000. Intech Investment Management LLC lifted its position in shares of Fulcrum Therapeutics by 74.9% during the 4th quarter. Intech Investment Management LLC now owns 30,499 shares of the company's stock worth $143,000 after buying an additional 13,057 shares during the last quarter. Wells Fargo & Company MN boosted its stake in Fulcrum Therapeutics by 34.4% in the fourth quarter. Wells Fargo & Company MN now owns 34,264 shares of the company's stock valued at $161,000 after buying an additional 8,761 shares in the last quarter. Finally, Bailard Inc. bought a new position in Fulcrum Therapeutics in the fourth quarter valued at about $169,000. 89.83% of the stock is owned by institutional investors.

Analyst Ratings Changes

Separately, HC Wainwright restated a "neutral" rating and issued a $4.00 price target on shares of Fulcrum Therapeutics in a research note on Wednesday, February 26th. One analyst has rated the stock with a sell rating, six have given a hold rating and two have given a buy rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Hold" and an average price target of $8.63.

Fulcrum Therapeutics Trading Down 2.7 %

NASDAQ:FULC traded down $0.10 during mid-day trading on Wednesday, hitting $3.55. 517,057 shares of the company's stock were exchanged, compared to its average volume of 939,524. Fulcrum Therapeutics, Inc. has a fifty-two week low of $2.32 and a fifty-two week high of $10.13. The company has a 50 day simple moving average of $3.15 and a 200-day simple moving average of $3.61. The firm has a market capitalization of $191.63 million, a P/E ratio of -11.45 and a beta of 2.13.

Fulcrum Therapeutics (NASDAQ:FULC - Get Free Report) last issued its quarterly earnings results on Tuesday, February 25th. The company reported ($0.31) earnings per share for the quarter, missing the consensus estimate of ($0.28) by ($0.03). As a group, analysts expect that Fulcrum Therapeutics, Inc. will post -0.16 earnings per share for the current year.

Fulcrum Therapeutics Company Profile

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.